The Santa Clara, Calif.-based company Cardiva Medical Inc. announced April 5 it has received an expanded indication from US FDA for Vascade. The vascular closure system, which was already approved in 2013 for arterial closures, is now also approved for difficult femoral vein closures.
The company argues that not only does this mean better treatment for patients undergoing interventional cardiac catheterization surgery, but also greatly increases their market footprint.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?